KPV

KPV Regulatory Status

UKPWritten and published by UK Peptides2 min readUpdated 4 cited sources

The short answer

KPV holds no marketing authorisation from the MHRA, EMA or FDA and has not been through regulatory review in any jurisdiction. There is no registered interventional trial programme and no human clinical data, so it is supplied for laboratory research only, with no claim made about inflammation or any condition in any person.

Key facts

MHRA status
Not authorised
EMA status
Not authorised
FDA status
Not approved
Clinical trials
None established
UK supply basis
Laboratory research only
Specific risk
Anti-inflammatory indication language

The position

No regulator has assessed KPV. There is no marketing authorisation in any jurisdiction, no registered interventional trial programme, and no route by which laboratory research material becomes a medicine. It is supplied here on the same basis as everything else in the catalogue.

Why this category's literature is a particular hazard

The published work is anti-inflammatory and includes colitis models, so it is research framed around a disease. That framing makes it unusually easy to slide from reporting a study to implying a treatment, because the vocabulary of the literature is already the vocabulary of an indication. The distance between mice with induced colitis and a person with inflammatory bowel disease is the whole distance that matters.

Research material referenced

KPV 10mg, third-party HPLC tested

Buy KPV · £28.99

What is said here and what is not

Reported: that KPV is the C-terminal tripeptide of alpha-MSH, that studies describe effects on NF-κB signalling and cytokine production in cell culture, and that a 2008 paper reported anti-inflammatory potential in murine colitis. Not said: that it treats, reduces or affects inflammation in any person. The first set is fact about published work; the second would be a therapeutic claim.

The enforcement context

The MHRA opened investigations into UK retailers making therapeutic claims about unregulated peptide products in April 2026. The framework turns on the claim and the intended use rather than the compound, and an anti-inflammatory claim about a research chemical is squarely within what it addresses.

What would change the position

An application to and assessment by the MHRA. For KPV that would first require the clinical development that does not currently exist: no registered trials, no human data, and no defined molecular target.

Frequently asked questions

Why is the anti-inflammatory literature a compliance risk?

Because the vocabulary of the research is already the vocabulary of an indication, which makes sliding from reporting a study to implying a treatment unusually easy.

Are there registered trials?

None established. There is no human clinical data for KPV.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More KPV articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.